This year’s Lupus Research Alliance (LRA) Breaking Through Gala, billed as the world’s largest single lupus fundraising event, took in $3 million for research into the autoimmune disorder. Some 600 members of the global lupus community turned out for the Nov. 25 New York City affair that celebrates…
Treatment with an investigational antibody therapy known as BIIB059 was well-tolerated and decreased disease activity in people with cutaneous lupus erythematosus (CLE) — lupus affecting the skin — with or without systemic lupus erythematosus (SLE), which affects other organs and systems, top-line results of a Phase 2 study…
Adding the experimental oral therapy voclosporin to standard-of-care treatment is safe and nearly doubles the proportion of complete kidney responses in people with lupus nephritis, according to top-line data from a Phase 3 study. Aurinia Pharmaceuticals, the company developing voclosporin, hopes to make the treatment available to…
Adding RC18 (telitacicept) to standard therapy significantly lowered disease activity in systemic lupus erythematosus (SLE) patients in a Phase 2b trial, data show. The treatment was also well-tolerated. Researchers at RemeGen, the company developing RC18, presented the findings, “A Human Recombinant Fusion Protein Targeting B…
The Lupus Foundation of America (LFA) marked the 10th year of its Evening of Hope Gala by honoring leaders in the fight against lupus while raising funds to advance the nonprofit’s mission. Hundreds of advocates and community members gathered in New York City to recognize the efforts…
Oral treatment with cenerimod shows promising safety and efficacy in people with mild to moderate systemic lupus erythematosus (SLE), including reduced disease activity and lower levels of immune cells in the blood, according to data from a Phase 2 trial. The research, “First Use of Cenerimod, a Selective…
Adding investigational anifrolumab to standard therapy lowers disease activity, limits the need for corticosteroids, and eases skin symptoms in people with moderate to severe systemic lupus erythematosus (SLE), a Phase 3 clinical trial shows. Trial results were discussed in a presentation titled “A Phase 3…
Adding Gazyva (obinutuzumab) to standard-of-care treatment more than doubles the proportion of complete kidney responses in people with proliferative lupus nephritis, a Phase 2 study shows. A Phase 3 study of Gazyva in lupus nephritis is expected to start next year. The findings were presented at two meetings…
The Lupus Foundation of America (LFA) is partnering with health informatics company Prometheus Research to develop a next-generation data platform, set to launch next year, to help advance lupus research. LFA will use the platform to expand its Research.forME Lupus Registry, which was launched in 2017…
Adding anifrolumab to standard-of-care treatment significantly reduced disease activity, corticosteroid use, and severity of skin lesions in people with moderate-to-severe systemic lupus erythematosus (SLE), according to data from a Phase 3 trial. The research, “Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus…